MDGEF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Medigene AG MDGEF'ün son çeyrekteki geliri nasıl performans gösterdi?
Medigene AG'in gelir tahmini nedir?
Medigene AG'in kazanç kalite puanı nedir?
Medigene AG kazançlarını ne zaman rapor eder?
Medigene AG'in beklenen kazançları nelerdir?
Medigene AG kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$2.59
Açılış fiyatı
$2.59
Günün Aralığı
$0.1 - $2.59
52 haftalık aralık
$0.1 - $2.59
İşlem hacmi
10.0K
Ort.Hacim
0
EPS (TTM)
-1.28
Dividend yield
--
Piyasa Değeri
$38.1M
MDGEF nedir?
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.